Literature DB >> 27170397

Acute Liver Failure - It's Just a Matter of Cell Death.

Jan-Peter Sowa1, Guido Gerken, Ali Canbay.   

Abstract

BACKGROUND: Acute liver failure (ALF) is characterized by a sudden loss of hepatic function due to hepatocyte cell death and dysfunction in previously healthy individuals. The clinical presentation of ALF is associated with coagulopathy (international normalized ratio ≥1.5) and hepatic encephalopathy, although the latter may be less pronounced. Without appropriate and timely intensive care or liver transplantation (LTx), ALF will result in multi-organ failure and death. Various causes may induce ALF, with acetaminophen (APAP) intoxication and acute hepatitis B infection as most common causes in industrialized countries. While conventional terminology discerns acute, acute-on-chronic and acute-on cirrhosis liver failure, some chronic liver diseases (i.e. autoimmune hepatitis (AIH), Wilson's disease) can remain undiagnosed until an initial presentation as ALF. KEY MESSAGES: Upon definite diagnosis of ALF, the underlying cause must be identified, since etiology affects prognosis and clinical management. Individual prognosis should be evaluated with one of various available scoring systems. Most widely used are Model for End-Stage Liver Disease, the King's College Criteria and the Clichy criteria. Other markers, that is, cell death markers, lactate or thyroid status, may improve diagnostic accuracy of classic scores, though routine use of these is not yet established. Etiology-specific treatment under intensive care should be performed, if possible (APAP and amanita intoxication, acute viral hepatitides and AIH). LTx is the only curative option for other causes, unknown reasons of ALF or when etiology-specific therapy fails. In ambiguous cases, that is, suspected drug induced ALF or AIH, co-infection with hepatitis E virus should be tested, as this might be more common than it is currently supposed to be.
CONCLUSIONS: Despite major improvements in clinical management of ALF patients, a significant proportion of ALF cases remains without clear identification of the underlying cause or unrecognized multiple causes. In depth analyzes of ambiguous ALF cases is warranted to further improve clinical management.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27170397     DOI: 10.1159/000444557

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  5 in total

1.  Krüppel-like factor 6 is a transcriptional activator of autophagy in acute liver injury.

Authors:  Svenja Sydor; Paul Manka; Jan Best; Sami Jafoui; Jan-Peter Sowa; Miguel Eugenio Zoubek; Virginia Hernandez-Gea; Francisco Javier Cubero; Julia Kälsch; Diana Vetter; Maria Isabel Fiel; Yujin Hoshida; C Billie Bian; Leonard J Nelson; Han Moshage; Klaas Nico Faber; Andreas Paul; Hideo A Baba; Guido Gerken; Scott L Friedman; Ali Canbay; Lars P Bechmann
Journal:  Sci Rep       Date:  2017-08-14       Impact factor: 4.379

Review 2.  Roles of hepatic stellate cells in acute liver failure: From the perspective of inflammation and fibrosis.

Authors:  Juan Li; Ying-Ren Zhao; Zhen Tian
Journal:  World J Hepatol       Date:  2019-05-27

3.  Paramylon from Euglena gracilis Prevents Lipopolysaccharide-Induced Acute Liver Injury.

Authors:  Yunhao Xie; Jin Li; Huan Qin; Qing Wang; Zixi Chen; Chengyu Liu; Ling Zheng; Jiangxin Wang
Journal:  Front Immunol       Date:  2022-01-11       Impact factor: 7.561

4.  Kahweol Protects against Acetaminophen-Induced Hepatotoxicity in Mice through Inhibiting Oxidative Stress, Hepatocyte Death, and Inflammation.

Authors:  Jung-Yeon Kim; Jaechan Leem; Gyun Moo Kim
Journal:  Biomed Res Int       Date:  2022-02-27       Impact factor: 3.411

5.  Recombinant Human HPS Protects Mice and Nonhuman Primates from Acute Liver Injury.

Authors:  Yang Yang; Huali Zhai; Yue Wan; Xiaofang Wang; Hui Chen; Lihou Dong; Taoyun Liu; Guifang Dou; Chutse Wu; Miao Yu
Journal:  Int J Mol Sci       Date:  2021-11-28       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.